Every cannabis brand with a copywriter has discovered the endocannabinoid system, and most of them use it the way a moisturiser label uses "dermatologist": as a word that sounds like a mechanism. The system itself is real, mapped in detail since the early 1990s, and worth twenty minutes of your attention if you take edibles for sleep, pain or anxiety, because the four things it explains decide whether a product is worth buying twice. The dispensary brands with the strongest product mostly skip the word and print a milligram figure instead, which turns out to be the sentence that means something.
Lu and Mackie's 2016 introduction in Biological Psychiatry is the cleanest short account of how the system works. Endocannabinoids are made on demand rather than stored, released in one or two quick enzymatic steps when a neuron is busy, and 2-AG in particular acts as a retrograde messenger, sent backwards across the synapse to tell the upstream neuron to ease off. THC borrows that machinery. It does not add anything to it.
What is the endocannabinoid system, in plain terms?
A signalling system with three parts: two receptors (CB1, the abundant one in the brain and nervous system, and CB2, found mostly in immune tissue), two main molecules the body makes to act on them (anandamide and 2-AG), and the enzymes that build and clear those molecules. THC produces its intoxication, and most of its medical effects, through the first receptor.
The dates matter because they are recent. Mechoulam and Parker's 2013 review in the Annual Review of Psychology opens with the timeline: THC was isolated in the mid-1960s, and the receptors and the body's own cannabinoids were identified only 20 to 25 years later. Devane and colleagues found the first endocannabinoid in 1992, in Science, as an arachidonic acid derivative pulled from pig brain that behaved like THC at the receptor. They named it anandamide. Munro, Thomas and Abu-Shaar cloned the second receptor in Nature the following year and found it in macrophages in the spleen rather than in the brain, which is why CB2 became the immune receptor and CB1 the one that gets you high. Zou and Kumar's 2018 review of the CB1 story makes the point the label never does: the psychoactive effects that make THC a product are the same ones that have kept cannabinoids out of most of clinical practice.
Cristino, Bisogno and Di Marzo's 2020 review in Nature Reviews Neurology adds an "expanded endocannabinoid system", the endocannabinoidome, with its own mediators, receptors and enzymes. The system kept getting bigger as people looked at it. The label copy kept getting simpler.
Why does THC get you high and CBD doesn't?
Because THC is a partial agonist at CB1 and CBD barely binds the same site. Pertwee's 2008 review puts CBD's affinity for CB1 in the micromolar range, roughly a hundredfold weaker than THC, and Laprairie's 2015 cell study found that CBD's main action at CB1 is to lower the receptor's response to THC rather than to switch it on.
The numbers are worth having, because they are the actual difference between the two molecules on the tin. In Pertwee's review (British Journal of Pharmacology), THC is a partial agonist at both receptors, which means it activates CB1 without reaching the ceiling the body's own 2-AG can, and its effects depend on how many receptors are available and how much endocannabinoid signalling is already under way. The affinity table in the same review lists THC's CB1 binding constant at 5 to 80 nanomolar across six labs, and CBD's at 4,350 to more than 10,000. Yet CBD blocks cannabinoid agonists in brain membranes at 79 and 138 nanomolar, far below what its binding affinity predicts, a paradox Pertwee flags and leaves open.
Laprairie, Bagher, Kelly and Denovan-Wright closed it in 2015, in the same journal. CBD behaves as a non-competitive negative allosteric modulator of CB1: it binds a different spot on the receptor, with an estimated affinity of about 304 nanomolar against more than 4 micromolar for the site THC uses, and from there it reduces both the potency and the maximal effect of THC and of 2-AG. On its own it managed only weak partial agonism above 2 micromolar. The authors conclude that this allosteric effect, plus actions that have nothing to do with CB1, has to explain what CBD does in a person. Our CBN versus CBD piece covers two of those other targets, the 5-HT1A serotonin receptor and adenosine reuptake, both at concentrations a gummy does not produce in a human brain.
So the honest version of the shelf's two-word pharmacology is that CBD is barely a CB1 drug at all. THC acts on the receptor that produces intoxication, and CBD mostly acts somewhere else, at doses the trials used and the gummies do not.
Why does my edible stop working, and how fast does that reverse?
Because daily stimulation lowers the number of CB1 receptors available, and stopping raises it again. Two PET studies rescanned chronic users after they stopped: Hirvonen 2012 found cortical CB1 binding about 20% lower and back to normal in most regions after about four weeks, and D'Souza 2016 found a 15% deficit that stopped being statistically significant after two days.
Two more PET studies, Ceccarini 2015 and Spindle 2021, scanned once and found deficits of similar size still there within the first week, and none of the four recruited people for eating cannabis. Our tolerance explainer sets them side by side with the oral THC studies. Hirvonen and colleagues at the NIH admitted 30 men who smoked an average of 10 joints a day, for an average of 12 years, to a closed research unit and scanned them on arrival and again after about four weeks of monitored abstinence. At baseline, CB1 binding was about 20% lower than in 28 controls in the neocortex and limbic cortex, with no difference in the basal ganglia, thalamus, brainstem or cerebellum, and the longer a man had smoked, the lower the cortical number. After about four weeks, binding had returned to normal in most regions, in the 14 men who stayed for the second scan. D'Souza and colleagues at Yale scanned 11 cannabis-dependent men, smoking about 2 joints a day, against 19 controls and found availability 15% lower across almost every region, about the same deficit at a fifth of the use. It was still lower at two days and at 28, no longer by a statistically significant margin. Lower availability on day two also went with worse withdrawal that day.
The table shows what each PET study scanned, what it found at baseline, and how fast the deficit closed.
| Study | Who was scanned | Baseline deficit | Recovery observed |
|---|---|---|---|
| Hirvonen 2012 | 30 men smoking about 10 joints a day for an average of 12 years, against 28 controls | CB1 binding about 20% lower in neocortex and limbic cortex, unchanged in subcortical regions, lower the longer they had smoked | Back to normal in most regions after about 4 weeks of monitored abstinence (14 men had the second scan), though not the hippocampus |
| D'Souza 2016 | 11 cannabis-dependent men smoking about 2 joints a day, against 19 controls | 15% lower CB1 availability across almost all regions | Still lower at 2 days (10 men) and 28 days (8 men), no longer statistically significant |
Our tolerance-break guide turns these numbers into a patient's reset plan. Two things in the receptor story matter for an edible patient. The first is that the reversal starts in days and is not finished in days, and that nobody has measured when a dose works again. The second is the regional pattern: Hirvonen's downregulation was cortical and absent in the subcortical regions, and the authors floated the idea that the high and motor effects resist tolerance because they depend on those spared regions. They also called the idea simplistic, and D'Souza's men showed deficits in subcortical regions too.
The forum record has been running this experiment without a scanner. In a Straight Dope thread opened in May 2025, a poster who had been eating homemade edibles every day for a few weeks reported going from half a gram of flower per dose to a gram and a half and getting, in their words, basically nowhere, and asked whether a 30-day break was required. The reply came three days later, from a poster who uses half a gummy, never twice in a day, and takes one to three days off whenever the effect fades, which puts them, in their words, right back at square one. A tripling of the dose in a few weeks, and a reset measured in days. Neither number came from a scanner, and no paper has tested either one.
Why does a 1:1 gummy feel different from a THC-only gummy?
Partly because CBD lowers CB1's response to THC in the dish, and mostly because the gummy carries less THC. The human trials complicate the label: Solowij 2019 found 4mg of CBD increased THC intoxication while 400mg reduced it, and Englund 2023 found 10 to 30mg of CBD beside 10mg of THC changed nothing.
In the dish, below a micromolar, CBD raises how much THC it takes to activate CB1 and lowers how big the response gets, which is Laprairie's result. Mechoulam and Parker supply the other half, which is that endocannabinoid effects are often biphasic, with low doses producing the opposite of high doses, a pattern our generalized anxiety page describes for THC on its own. Put those together and a 1:1 gummy should be a gentler THC gummy. When people were given the combination and measured, the gentleness depended on a CBD dose no gummy carries.
Solowij and colleagues (2019, European Archives of Psychiatry and Clinical Neuroscience) vaporised 8mg of THC alone, with 4mg of CBD, or with 400mg of CBD in 36 frequent and infrequent users. The 400mg dose reduced intoxication. The 4mg dose increased it, most clearly in the infrequent users. Englund and colleagues (2023, Neuropsychopharmacology) gave 46 infrequent users 10mg of vaporised THC with 0, 10, 20 or 30mg of CBD, the ratios on most dispensary shelves, and found that no CBD dose changed the memory impairment, the psychotic symptoms, the subjective high or anything else the THC produced. Their conclusion, that at the ratios common in medicinal and recreational products there is no evidence CBD protects against THC's acute effects, is the sentence to carry into the aisle.
Neither trial used a gummy, and swallowed CBD is absorbed poorly, so the oral picture is thinner still. What a 1:1 gummy at 5mg of each reliably delivers is 5mg of THC, which sits in the low tier of the ladder our dosing guide owns: microdose 1 to 2.5mg, low 2.5 to 5mg, moderate 5 to 15mg, high 15 to 30mg, 30mg and above very high. The THC versus CBD guide suggests 5mg and 5mg as a first experiment, and that holds up for exactly this reason: the THC number is doing the work you can count on. Wana's blog tells readers, as part of its advice for coming down from too much THC, that THC and CBD "work synergistically within your endocannabinoid system". The one controlled trial at dispensary ratios found the two molecules ignoring each other.
What does "balancing your endocannabinoid system" on a label mean?
Nothing a buyer can check. No gummy measures endocannabinoid tone, no placebo-controlled trial has shown a 25mg CBD gummy changes it, and the system the phrase names includes the receptor behind every unwanted effect of THC. The word on the jar signals that the brand has read about the receptors, and that is all it signals.
The copy is easy to find because the hemp side of the market leans on it. On November 7, 2026, the +PlusCBD gummies collection page told shoppers that its gummies "help your overall health in a myriad of ways by balancing your endocannabinoid system or ECS", that CBD "improves your endocannabinoid tone", and, a few lines later, that CBD "interacts with the body's endocannabinoid system to provide relief from conditions such as anxiety, pain, and inflammation". That last one reads like a drug claim on a gummy. The ones before it are the interesting kind of empty. Endocannabinoid tone is a real research idea, the proposal that baseline endocannabinoid signalling varies between people and runs low in some conditions; our chronic pain page covers the clinical endocannabinoid deficiency hypothesis it comes from. Nobody at a hemp company has measured yours, and no gummy arrives with a before and after.
The dispensary side mostly skips the word. The same day, it did not appear on Kiva's homepage or on Papa and Barkley's, and the sentence those brands print instead is a milligram figure per gummy. That sentence names a dose of a partial agonist at a receptor whose cortical density, per Hirvonen, tracks how many days in a row you have taken it. "Supports your ECS" names nothing, because the system has no setting called supported. What it has, per Cristino's review, is a CB1 receptor whose activation produces the central effects that have limited every drug built to switch it on or off. If a label could truthfully say it activated your endocannabinoid system, that would be a warning.
What does the endocannabinoid system not explain about your gummy?
The wait. Every receptor event on this page happens after THC arrives, and with an edible the arrival takes 30 minutes to 2 hours, with the peak at 2 to 3 hours, per our edible duration guide, which owns those numbers. The gap between swallowing and the high belongs to your gut and liver, and no receptor explains it.
The questions the system answers decide whether to keep buying a product: why CBD never did anything for your sleep, why a 1:1 is a 5mg gummy with a footnote, why the dose crept. The question it never answers is the one people take the second gummy over, and that one has its own page, our guide for taking too much, and the dosing guide's standing answer, which is to wait the full two hours before judging. The receptors will still be there.